
Vitaliy Mykytiv

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7151234/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Minimal Residual Disease in Multiple Myeloma: Potential for Blood-Based Methods to Monitor Disease. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, e34-e40.	0.4	1
2	The first case of acute myeloid leukaemia/myeloid sarcoma with cytokeratin expression on blasts diagnosed on urine specimen. Hematology/ Oncology and Stem Cell Therapy, 2021, 14, 343-347.	0.9	3
3	Platelet hyperactivation in multiple myeloma is also evident in patients with premalignant monoclonal gammopathy of undetermined significance. British Journal of Haematology, 2021, 192, 322-332.	2.5	9
4	Extramedullary pericardial haematopoiesis as a presenting feature of chronic myeloid leukaemia. British Journal of Haematology, 2021, 194, 7-7.	2.5	0
5	A panhaemocytometric approach to COVID-19: a retrospective study on the importance of monocyte and neutrophil population data on Sysmex XN-series analysers. Clinical Chemistry and Laboratory Medicine, 2021, 59, e169-e172.	2.3	11
6	Platelet hyperactivation and hyporesponsiveness at diagnosis in multiple myeloma persists during treatment initiation. Thrombosis Research, 2021, 203, 186-189.	1.7	0
7	Examining the Usefulness of the Charlson Comorbidity Index to Predict Early Mortality in Patients with Acute Myeloid Leukaemia. Blood, 2021, 138, 1218-1218.	1.4	0
8	Cybord-Dara in Newly Diagnosed Transplant-Eligible Multiple Myeloma: Follow up Results from the 16-Bcni-001/Ctrial-IE 16-02 Study Show High Rates of MRD Negativity at End of Treatment. Blood, 2021, 138, 2756-2756.	1.4	1
9	Repeat JAK2 V617F testing in patients with suspected essential thrombocythaemia. Journal of Clinical Pathology, 2020, 73, 772-772.	2.0	1
10	Molecular responses in e19a2 BCR-ABL1 chronic myeloid leukemia. Leukemia Research Reports, 2020, 13, 100195.	0.4	0
11	Leukostasis as a result of rapidly progressive granulocytosis in a patient diagnosed with MDS/MPN-U. Blood, 2019, 134, 2117-2117.	1.4	0
12	CyBorD-DARA is potent initial induction for MM and enhances ADCP: initial results of the 16-BCNI-001/CTRIAL-IE 16-02 study. Blood Advances, 2019, 3, 1815-1825.	5.2	19
13	A multicenter report on the natural history of myelodysplastic syndromes in very old patients (aged) Tj ETQq1 1	0.784314 1.3	rgBT /Over
14	Double CD38â^'/CD138â^' negative multiple myeloma. Hematology/ Oncology and Stem Cell Therapy, 2019, 12, 64-66.	0.9	8
15	Anemia in patient with primary hyperoxaluria and bone marrow involvement by oxalate crystals. Hematology/ Oncology and Stem Cell Therapy, 2018, 11, 118-121.	0.9	9
16	Should Myelodysplastic Syndromes in Very Old Patients be More Actively Managed? Clinical Characteristics, Management and Outcomes for Patients 85 Years and Older. Blood, 2018, 132, 5515-5515.	1.4	0
17	Cybord-Dara Is a Highly Effective Upfront Treatment for Newly Diagnosed Multiple Myeloma. Initial Efficacy Results of the 16-Bcni-001/Ctrial-IE (ICORG) 16-02 Study. Blood, 2018, 132, 3242-3242.	1.4	0